Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2015 18:00 ET | Source: MediciNova, Inc.

MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona

LA JOLLA, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 25, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina

LA JOLLA, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 16, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS

LA JOLLA, Calif., Feb. 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 10, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF

LA JOLLA, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 03, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of NASH

LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 02, 2015 18:00 ET | Source: MediciNova, Inc.

MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC

LA JOLLA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 01, 2015 18:00 ET | Source: MediciNova, Inc.

MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC

LA JOLLA, Calif., Feb. 1, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
January 29, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives New Patent Covering MN-029 (denibulin) di-hydrochloride in Japan

LA JOLLA, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
January 28, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces an Open Investigational New Drug (IND) Application for MN-001 in NASH

LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
December 09, 2014 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Liver Disorders

LA JOLLA, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...